Total solar irradiance during the last five centuries

The total solar irradiance (TSI) varies on timescales of minutes to centuries. On short timescales it varies due to the superposition of intensity fluctuations produced by turbulent convection and acoustic oscillations. On longer timescales, it changes due to photospheric magnetic activity, mainly because of the facular brightenings and dimmings caused by sunspots. While modern TSI variations have been monitored from space since the 1970s, TSI variations over much longer periods can only be estimated either using historical observations of magnetic features, possibly supported by flux transport models, or from the measurements of the cosmogenic isotope (e.g., 14C or 10Be) concentrations in tree rings and ice cores. The reconstruction of the TSI in the last few centuries, particularly in the 17th/18th centuries during the Maunder minimum, is of primary importance for studying climatic effects. To separate the temporal components of the irradiance variations, specifically the magnetic cycle from secular variability, we decomposed the signals associated with historical observations of magnetic features and the solar modulation potential Φ by applying an empirical mode decomposition algorithm. Thus, the reconstruction is empirical and does not require any feature contrast or field transport model. The assessed difference between the mean value during the Maunder minimum and the present value is ≃2.5 W m−2. Moreover it shows, in the first half of the last century, a growth of ≃1.5 W m−2, which stops around the middle of the century to remain constant for the next 50 years, apart from the modulation due to the solar cycle

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study

Background: Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. Objectives: To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis. Methods: SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks. Results: In total, 434 patients were recruited: 185 (42\ub76%) were Cw6-POS and 246 (56\ub77%) were Cw6-NEG (three not assessed). Mean \ub1 SD age was 45\ub72 \ub1 13\ub72 years (Cw6-POS 42\ub77 \ub1 13\ub71; Cw6-NEG 47\ub72 \ub1 12\ub79). The baseline PASI score was comparable between the cohorts [Cw6-POS 20\ub77 \ub1 8\ub799; Cw6-NEG 21\ub75 \ub1 9\ub799 (P = 0\ub7777)]. At week 16, PASI 90 was achieved in 80\ub74% of Cw6-POS and 79\ub77% of Cw6-NEG patients (difference 0\ub776; 95% confidence interval 127\ub704 to 8\ub723). No differences in absolute PASI at week 16 (Cw6-POS 1\ub736 \ub1 3\ub758; Cw6-NEG 1\ub718 \ub1 2\ub729) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42\ub77%; Cw6-NEG 49\ub76% (P = 0\ub7295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI. Conclusions: Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status

L'impiego della lectina Dolichos Biflorus agglutinina (DBA) nello studio del morbo di Paget

[no abstract available

La sindrome da Iper IgE

[no abstract available